ArticleJournal of Korean medical science2025
Correlating Urinary Tract Infection Risks With Sodium-Glucose Cotransporter-2 Inhibitors: Insights From the National Health Insurance Data of Korea.
Article in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-Acute Sequelae of COVID-19 Across 15 Major Health Domains and 67 Diseases in Individuals With Depressive Disorder: A Korean Nationwide Cohort Study.Journal of Korean medical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIn this study, we aimed to investigate the correlation between the use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) and the risk of urinary tract infections (UTIs) in patients with type 2 diabetes mellitus (T2DM), based on data from the National Health Insurance Service (NHIS) in South Korea.
methodsThis retrospective, population-based cohort study was conducted using NHIS data. As a part of a dual-therapy regimen, either SGLT2is or any other anti-diabetic agent, was administered in patients diagnosed with T2DM and under metformin therapy. The incidence of UTIs was measured and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. Kaplan-Meier survival analysis was performed to estimate the cumulative incidence of UTIs.
resultsThis study included 27,128 patients, of whom 1,274 were treated with SGLT2is. The HR for the incidence of UTIs in SGLT2i users compared to the control group was 0.874 (95% CI, 0.585-1.309;
conclusionIn this large population-based cohort study, the use of SGLT2is was not associated with a statistically significant increase in the risk of UTIs. Although SGLT2i use is linked to increased glucose excretion in urine, this study indicates that the clinical impact on UTI risk is minimal. Overall, continuous monitoring and patient education regarding UTI symptoms remain to be important in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.